An individual patient data meta-analysis on characteristics, treatments and outcomes of the glioblastoma/gliosarcoma patients with central nervous system metastases reported in literature until 2013
Dissemination of high-grade gliomas (WHO IV) has been investigated poorly so far. We conducted an extensive analysis of the characteristics, treatments and outcomes of the glioblastoma multiforme (GBM)/gliosarcoma (GS) patients with central nervous system (CNS) metastases reported in literature until April 2013. PubMed and Web of Science searches for peer-reviewed articles pertaining to GBM/GS patients with metastatic disease were conducted using predefined keywords. Additionally, we performed hand search following the references from the selected papers. Cases in which the metastases exclusively occurred outside the CNS were excluded. 110 publications reporting on 189 patients were eligible. There was a significant increase in the number of reported cases over the last decades. We calculated a median overall survival from diagnosis of metastasis (from initial diagnosis of GBM/GS) of 3.0 ± 0.3 (11 ± 0.7) months. On univariate analyses, gender, age, the histological subtype, the time interval between initial diagnosis and the occurrence of metastases and the location of CNS metastasis (intracranial versus spinal and parenchymal versus leptomeningeal, respectively) did not influence survival after diagnosis of metastasis. There was no substantial treatment progress over the recent decades. GBM/GS with CNS metastasis are associated with a dismal prognosis. Crucial treatment progress is not evident. A central registry should be considered to consecutively gain more information about the ideal therapeutic approach.
KeywordsGlioblastoma Gliosarcoma CNS Metastasis Metastatic Individual patient data meta-analysis
We are indebted to the authors of articles, who provided the data to this study that otherwise would have not been possible. We would like to thank Mrs. Christiane Hofmann for assisting the literature search.
Conflict of interest
The author(s) indicated no potential conflicts of interest.
This manuscript is in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its subsequent amendments.
- 2.Vertosick FT Jr, Selker RG (1990) Brain stem and spinal metastases of supratentorial glioblastoma multiforme: a clinical series. Neurosurgery 27 (4):516–521; discussion 521–512Google Scholar
- 4.Müller K, Schlamann A, Guckenberger M, Warmuth-Metz M, Gluck A, Pietschmann S, Wawer A, Kortmann RD, Kramm C, von Bueren AO (2014) Craniospinal irradiation with concurrent temozolomide for primary metastatic pediatric high-grade or diffuse intrinsic pontine gliomas. A first report from the GPOH-HIT-HGG Study Group. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 190 (4):377–381. doi: 10.1007/s00066-013-0513-0
- 7.Stupp R, Mason WP, van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352(10):987–996. doi: 10.1056/NEJMoa043330 PubMedCrossRefGoogle Scholar
- 14.Galanis E, Buckner JC, Dinapoli RP, Scheithauer BW, Jenkins RB, Wang CH, O’Fallon JR, Farr G Jr (1998) Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. J Neurosurg 89(3):425–430. doi: 10.3171/jns.1998.89.3.0425 PubMedCrossRefGoogle Scholar
- 18.Olson JJ, Nayak L, Ormond DR, Wen PY, Kalkanis SN, Committee ACJG (2014) The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. J Neuro Oncol 118(3):501–555. doi: 10.1007/s11060-013-1338-5 CrossRefGoogle Scholar
- 19.Olson JJ, Nayak L, Ormond DR, Wen PY, Kalkanis SN, Ryken TC, Committee ACJG (2014) The role of targeted therapies in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. J Neuro Oncol 118(3):557–599. doi: 10.1007/s11060-013-1339-4 CrossRefGoogle Scholar
- 20.Ryken TC, Aygun N, Morris J, Schweizer M, Nair R, Spracklen C, Kalkanis SN, Olson JJ, Committee ACJG (2014) The role of imaging in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. J Neuro Oncol 118(3):435–460. doi: 10.1007/s11060-013-1330-0 CrossRefGoogle Scholar
- 22.Ryu S, Buatti JM, Morris A, Kalkanis SN, Ryken TC, Olson JJ, Committee ACJG (2014) The role of radiotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. J Neuro Oncol 118(3):489–499. doi: 10.1007/s11060-013-1337-6 CrossRefGoogle Scholar
- 25.Müller K, Diez B, Muggeri A, Pietsch T, Friedrich C, Rutkowski S, von Hoff K, von Bueren AO, Zwiener I, Bruns F (2013) What’s in a name? Intracranial peripheral primitive neuroectodermal tumors and CNS primitive neuroectodermal tumors are not the same. Strahlenther Onkol 189(5):372–379. doi: 10.1007/s00066-013-0315-4 PubMedCrossRefGoogle Scholar
- 26.Moergel M, Meurer P, Ingel K, Wendt TG, Al-Nawas B (2011) Effectiveness of postoperative radiotherapy in patients with small oral and oropharyngeal squamous cell carcinoma and concomitant ipsilateral singular cervical lymph node metastasis (pN1): a meta-analysis. Strahlenther Onkol 187(6):337–343. doi: 10.1007/s00066-011-2206-x PubMedCrossRefGoogle Scholar